Market Overview

During the trading day on March 30, 2026, the Shanghai Composite Index posted a modest gain of 0.23 %, while the Shenzhen Component Index fell 0.12 % and the ChiNext Index declined 0.5 %. A total of 2,700 individual stocks recorded declines, yet several sectors displayed notable strength, particularly the pharmaceutical and aerospace‑related segments.

Pharmaceutical Sector Performance

The pharmaceutical segment continued its recent momentum, with several stocks recording multiple consecutive price increases.

  • Ningbo Menovo Pharmaceutical Co., Ltd. (Stock code 300054) secured a 7‑day, 6‑plate streak, indicating sustained investor interest.
  • Other performers included Wangbangde (万邦德), Shuanglu (双鹭药业), and Lianhuan (联环药业), all of which achieved consecutive upward plateaus.

The sector’s resilience aligns with the broader “innovation drug” theme that has attracted significant attention from market participants.

Stocks associated with commercial aviation and aerospace concepts also benefited from a rebound.

  • Shenjian (神剑股份) gained its third consecutive up‑plate.
  • Hengyuan Design (中衡设计) and Hengyuan Power (航天动力) both hit daily limits, reflecting investor optimism in the industry’s recovery.

Market Dynamics

  • Turnover: The combined trading volume for the Shanghai and Shenzhen markets reached 1.32 trillion Chinese yuan, up 180.3 billion yuan from the previous day.
  • Top Trades: The largest single‑day transaction involved Zhongji Xuchuang (中际旭创) with a volume of 8.6 billion yuan.
  • Sector Turnover: The aluminum and non‑ferrous metals group dominated the market, with notable up‑plates from Tianshan Aluminum (天山铝业) and Liyuan Co., Ltd. (利源股份).

Company‑Specific Highlights

Ningbo Menovo Pharmaceutical Co., Ltd.

  • Industry Position: Specializes in the manufacturing of pharmaceutical intermediates and active pharmaceutical ingredients, with its primary market in China.
  • Stock Metrics (as of 2026‑03‑26):
  • Closing price: 39.18 CNH
  • 52‑week high: 39.18 CNH
  • 52‑week low (2025‑04‑08): 11.40 CNH
  • Market capitalization: 7.85 billion CNH
  • Price‑earnings ratio: 79.12
  • Recent Performance: The stock has been part of a 7‑day, 6‑plate streak, underscoring robust investor confidence in its earnings prospects and product pipeline.

Investor Sentiment

The sustained activity in the pharmaceutical and aerospace segments suggests that investors remain receptive to companies with strong growth prospects in China’s high‑tech and life‑science sectors. The price‑earnings ratio, while elevated, is consistent with the broader valuation trend observed across the innovation‑drug sub‑sector.

Conclusion

The March 30 trading session highlighted the resilience of China’s pharmaceutical and aerospace sectors, with Ningbo Menovo Pharmaceutical Co., Ltd. contributing to the upward trend. Despite a broader decline in the Shenzhen Component Index, the market’s overall liquidity and sectoral gains indicate that investors continue to seek opportunities within high‑growth industries.